(VRDN) Viridian Therapeutics - Ratings and Ratios
Antibody, Eye, Disease, Drug
VRDN EPS (Earnings per Share)
VRDN Revenue
Description: VRDN Viridian Therapeutics
Viridian Therapeutics Inc (NASDAQ:VRDN) is a biotechnology company listed on the NASDAQ stock exchange, operating in the biotechnology sub-industry. The companys stock performance and financial health are critical indicators of its overall position in the market.
The stocks current price is $16.89, with various moving averages indicating a relatively stable trend. To evaluate the stocks potential, its essential to analyze key performance indicators (KPIs) such as revenue growth, research and development (R&D) expenses, and cash burn rate. A thorough examination of these metrics can provide insights into the companys operational efficiency and its ability to drive future growth.
With a market capitalization of $1.35 billion, Viridian Therapeutics Inc has a significant presence in the biotechnology sector. The companys price-to-earnings (P/E) ratio is not available due to negative earnings, which is common in the biotechnology industry where companies often prioritize R&D investments over profitability. Return on Equity (RoE) stands at -55.08%, indicating that the company is currently not generating profits for its shareholders.
Key economic drivers for Viridian Therapeutics Inc include the success of its R&D pipeline, particularly in the development of new therapies, and the overall demand for biotechnology products. The companys financial performance is also influenced by factors such as funding, partnerships, and regulatory approvals. Analyzing these drivers can help investors understand the companys potential for long-term growth and its ability to navigate the competitive biotechnology landscape.
To make informed investment decisions, its crucial to monitor Viridian Therapeutics Incs quarterly earnings reports, including the tax provision, to gauge the companys financial health and identify potential areas for improvement. By deconstructing the companys financials and operational metrics, investors can gain a deeper understanding of its strengths and weaknesses, ultimately informing their investment strategy.
VRDN Stock Overview
| Market Cap in USD | 1,563m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2014-06-18 |
VRDN Stock Ratings
| Growth Rating | -28.9% |
| Fundamental | 23.8% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -27.1% |
| Analyst Rating | 4.44 of 5 |
VRDN Dividends
Currently no dividends paidVRDN Growth Ratios
| Growth Correlation 3m | 91.1% |
| Growth Correlation 12m | -59.7% |
| Growth Correlation 5y | -0.1% |
| CAGR 5y | -4.47% |
| CAGR/Max DD 3y | -0.06 |
| CAGR/Mean DD 3y | -0.09 |
| Sharpe Ratio 12m | -1.56 |
| Alpha | 0.13 |
| Beta | 0.382 |
| Volatility | 56.68% |
| Current Volume | 549.3k |
| Average Volume 20d | 760.3k |
| Stop Loss | 17.5 (-6.2%) |
| Signal | 0.76 |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-344.1m TTM) > 0 and > 6% of Revenue (6% = 18.3k TTM) |
| FCFTA -0.40 (>2.0%) and ΔFCFTA -8.38pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 172.5k% (prev 189.2k%; Δ -16.7kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.53 (>3.0%) and CFO -309.1m > Net Income -344.1m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 11.01 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (81.6m) change vs 12m ago 27.78% (target <= -2.0% for YES) |
| Gross Margin 59.67% (prev -2268 %; Δ 2328 pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.05% (prev 0.05%; Δ 0.00pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -115.2 (EBITDA TTM -340.6m / Interest Expense TTM 2.96m) >= 6 (WARN >= 3) |
Altman Z'' -23.11
| (A) 0.90 = (Total Current Assets 578.8m - Total Current Liabilities 52.6m) / Total Assets 582.3m |
| (B) -2.03 = Retained Earnings (Balance) -1.18b / Total Assets 582.3m |
| warn (B) unusual magnitude: -2.03 — check mapping/units |
| (C) -0.58 = EBIT TTM -341.1m / Avg Total Assets 584.0m |
| (D) -17.61 = Book Value of Equity -1.18b / Total Liabilities 67.2m |
| Total Rating: -23.11 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 23.81
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield -22.80% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.04 = 2.50 |
| 5. Debt/Ebitda -0.06 = -2.50 |
| 6. ROIC - WACC -81.99% = -12.50 |
| 7. RoE -55.08% = -2.50 |
| 8. Rev. Trend -55.45% = -4.16 |
| 9. EPS Trend 39.43% = 1.97 |
What is the price of VRDN shares?
Over the past week, the price has changed by -7.67%, over one month by +3.04%, over three months by +17.06% and over the past year by -13.45%.
Is Viridian Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VRDN is around 16.07 USD . This means that VRDN is currently overvalued and has a potential downside of -13.88%.
Is VRDN a buy, sell or hold?
- Strong Buy: 9
- Buy: 5
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the VRDN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 38.4 | 105.8% |
| Analysts Target Price | 38.4 | 105.8% |
| ValueRay Target Price | 17.7 | -5% |
Last update: 2025-09-04 04:51
VRDN Fundamental Data Overview
CCE Cash And Equivalents = 563.4m USD (Cash And Short Term Investments, last quarter)
P/S = 5124.65
P/B = 4.7904
Beta = 0.482
Revenue TTM = 305.0k USD
EBIT TTM = -341.1m USD
EBITDA TTM = -340.6m USD
Long Term Debt = 12.4m USD (from longTermDebt, last quarter)
Short Term Debt = 8.99m USD (from shortTermDebt, last quarter)
Debt = 21.3m USD (Calculated: Short Term 8.99m + Long Term 12.4m)
Net Debt = -96.0m USD (from netDebt column, last quarter)
Enterprise Value = 1.02b USD (1.56b + Debt 21.3m - CCE 563.4m)
Interest Coverage Ratio = -115.2 (Ebit TTM -341.1m / Interest Expense TTM 2.96m)
FCF Yield = -22.80% (FCF TTM -232.8m / Enterprise Value 1.02b)
FCF Margin = -76.3k% (FCF TTM -232.8m / Revenue TTM 305.0k)
Net Margin = -112.8k% (Net Income TTM -344.1m / Revenue TTM 305.0k)
Gross Margin = 59.67% ((Revenue TTM 305.0k - Cost of Revenue TTM 123.0k) / Revenue TTM)
Tobins Q-Ratio = -0.86 (set to none) (Enterprise Value 1.02b / Book Value Of Equity -1.18b)
Interest Expense / Debt = 2.41% (Interest Expense 514.0k / Debt 21.3m)
Taxrate = 21.0% (US default)
NOPAT = -341.1m (EBIT -341.1m, no tax applied on loss)
Current Ratio = 11.01 (Total Current Assets 578.8m / Total Current Liabilities 52.6m)
Debt / Equity = 0.04 (Debt 21.3m / last Quarter total Stockholder Equity 515.2m)
Debt / EBITDA = -0.06 (Net Debt -96.0m / EBITDA -340.6m)
Debt / FCF = -0.09 (Debt 21.3m / FCF TTM -232.8m)
Total Stockholder Equity = 624.7m (last 4 quarters mean)
RoA = -59.08% (Net Income -344.1m, Total Assets 582.3m )
RoE = -55.08% (Net Income TTM -344.1m / Total Stockholder Equity 624.7m)
RoCE = -53.54% (Ebit -341.1m / (Equity 624.7m + L.T.Debt 12.4m))
RoIC = -74.73% (NOPAT -341.1m / Invested Capital 456.5m)
WACC = 7.27% (E(1.56b)/V(1.58b) * Re(7.34%)) + (D(21.3m)/V(1.58b) * Rd(2.41%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 8.36%
Discount Rate = 7.34% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -232.8m)
EPS Correlation: 39.43 | EPS CAGR: -7.24% | SUE: 0.0 | # QB: False
Revenue Correlation: -55.45 | Revenue CAGR: -63.46%
Additional Sources for VRDN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle